{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000023","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.134579+00:00","generated_at":"2026-06-02T23:51:06.519860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexicon Q1 net loss $48.4M; INPEFA sales $1.1M, up 63% QoQ","bullets":["Net loss of $48.4M ($0.20 per share) vs $31.9M ($0.17) in Q1 2023; SG&A jumped to $32.1M on launch spending.","Revenue of $1.1M from INPEFA (sotagliflozin) heart failure launch; market access ~40%, expansion expected H2 2024.","Cash and investments $355.6M as of March 31, up from $170M due to convertible preferred stock issuance in March.","NDA resubmission for ZYNQUISTA in type 1 diabetes with CKD expected mid-2024; Phase 3 for HCM to start mid-2024.","Enrollment on track for Phase 2b PROGRESS study of LX9211 in DPNP; topline data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000023","json":"https://secwatch.observer/filing/0001062822-24-000023.json","markdown":"https://secwatch.observer/filing/0001062822-24-000023.md","text":"https://secwatch.observer/filing/0001062822-24-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/0001062822-24-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/lxrx-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:51:06.519860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dacefd814c88dcc3f25515426e3dcc939f37081b","claim":"LEXICON PHARMACEUTICALS, INC. reported three months ended March 31, 2024 results: revenue $1.1 million, net income $48.4 million, or $0.20 per share.","evidence_excerpt":"continues to progress, with favorable feedback from healthcare providers and ongoing negotiations with payers regarding expanded market access. Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter. Market access remains at approximately 40% overall and is expected to expand in the second half of 2024. ZYNQUISTA","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/0001062822-24-000023-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$1.1 million"},{"label":"Net income","value":"$48.4 million, or $0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}